Mindfulness-based Psilocybin Therapy for PTSD

Brief summary

The goal of this study is to learn how psilocybin delivered with mindfulness-based therapy may help symptoms of posttraumatic stress disorder (PTSD). This is an assessor-blinded, randomized, controlled study in participants with PTSD. The study will investigate the changes in brain activity, connectivity, and microstructural neuroplasticity assessed using EEG/EMG and multimodal MRI measures after administration of one oral dose of psilocybin, accompanied either with standard "psychological support" only; or with standard support plus Mindfulness-based Cognitive Therapy (MBCT).

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

status

RECRUITING

phase

PHASE2

study type

INTERVENTIONAL

enrollment

30

sponsor

Anthony P King

conditions

Post Traumatic Stress Disorder; Depression - Major Depressive Disorder

interventions

COMBINATION_PRODUCT: Psilocybin + MBCT therapy; COMBINATION_PRODUCT: Active Comparator: Psilocybin with Support Only

start date

2026-09-01

start date type

ACTUAL

primary completion date

2029-09-01

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters